$515.79
argenx NV ADR is a biotechnology business based in the US. argenx NV ADR shares (ARGX) are listed on the NASDAQ and all prices are listed in US Dollars. argenx NV ADR employs 1,148 staff and has a trailing 12-month revenue of around $1.7 billion.
Our top picks for where to buy argenx NV ADR stock
How to buy argenx NV ADR stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – ARGX. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy argenx NV ADR stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
argenx NV ADR stock price (NASDAQ: ARGX)
Use our graph to track the performance of ARGX stocks over time.argenx NV ADR shares at a glance
Latest market close | $517.32 |
---|---|
52-week range | $327.73 - $540.49 |
50-day moving average | $485.21 |
200-day moving average | $418.37 |
Wall St. target price | $541.48 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-3.52 |
Is it a good time to buy argenx NV ADR stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
argenx NV ADR price performance over time
Historical closes compared with the close of $517.32 from 2024-08-30
1 week (2024-08-27) | 0.13% |
---|---|
1 month (2024-08-02) | 3.53% |
3 months (2024-06-03) | 36.89% |
6 months (2024-03-01) | 31.47% |
1 year (2023-09-01) | 0.50% |
---|---|
2 years (2022-09-02) | 37.84% |
3 years (2021-09-03) | 47.56% |
5 years (2019-09-03) | 303.53% |
argenx NV ADR financials
Revenue TTM | $1.7 billion |
---|---|
Gross profit TTM | $-251,786,000 |
Return on assets TTM | -5.51% |
Return on equity TTM | -5.74% |
Profit margin | -12.31% |
Book value | $71.28 |
Market Capitalization | $31.6 billion |
TTM: trailing 12 months
argenx NV ADR share dividends
We're not expecting argenx NV ADR to pay a dividend over the next 12 months.
argenx NV ADR share price volatility
Over the last 12 months, argenx NV ADR's shares have ranged in value from as little as $327.725 up to $540.49. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while argenx NV ADR's is 0.313. This would suggest that argenx NV ADR's shares are less volatile than average (for this exchange).
argenx NV ADR overview
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S. À. R.
Frequently asked questions
nullWhat percentage of argenx NV ADR is owned by insiders or institutions?
Currently 0.001% of argenx NV ADR shares are held by insiders and 58.148% by institutions. How many people work for argenx NV ADR?
Latest data suggests 1,148 work at argenx NV ADR. When does the fiscal year end for argenx NV ADR?
argenx NV ADR's fiscal year ends in December. Where is argenx NV ADR based?
argenx NV ADR's address is: Laarderhoogtweg 25, Amsterdam, Netherlands, 1101EB What is argenx NV ADR's ISIN number?
argenx NV ADR's international securities identification number is: US04016X1019 What is argenx NV ADR's CUSIP number?
argenx NV ADR's Committee on Uniform Securities Identification Procedures number is: 04016X101
More guides on Finder
-
Best options trading platforms of 2024
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
-
What is a covered call?
A covered call is an options trading strategy that allows you to generate income from stocks you already own.
-
6 stocks like Nvidia you need to consider
Advanced Micro Devices (AMD), Intel Corporation (INTC) and Qualcomm Inc (QCOM) are top stocks like Nvidia. See our full list here.
-
GSD Capital review 2024
A look at GSD Capital’s highlights, limitations, fees and investment strategies.
-
Frec review 2024: Low-cost direct indexing and individual stock trading
A deep dive into the highlights and limitations of Frec.
-
Public vs. Robinhood
Compare pros, cons, research tools and reviews for these two trading platforms.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
Interactive Brokers review 2024: Tailored trading and investing
Interactive Brokers has advanced charting tools but a high net requirement to qualify.
-
Top 15 tech stocks to invest in for 2024
Discover the top tech stocks poised to lead innovation and offer substantial growth opportunities.
-
Wealthfront review: Low-cost automated and DIY investing
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Ask a question